Glycostem will join NK2022 to present posters on 15 May, 2022 during the POSTER SESSION I, in Florida, United States.
25 Universal prospects of cryopreserved “off-the-shelf” umbilical cord blood CD34+ progenitor cell-derived NK cell therapeutics: Clinical and preclinical evaluation of GTA002 and genetically modified candidates
Adil D. Duru, Glycostem Therapeutics B.V.
29 Multimodal activation of ex vivo expanded GTA002 NK cells efficiently targets melanoma
Amanda A. Van Vliet, Glycostem Therapeutics
100 Enabling treatment options against colorectal cancer by enhancing functionality of stem cell derived NK cells
Nina Lamers, PhD, Glycostem Therapeutics